CINECA IRIS Institutional Research Information System

ROMEI, CRISTINA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 12.523
EU - Europa 6.632
AS - Asia 5.851
SA - Sud America 832
Continente sconosciuto - Info sul continente non disponibili 381
AF - Africa 362
OC - Oceania 8
Totale 26.589
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 12.183
IT - Italia 2.460
SG - Singapore 1.804
CN - Cina 1.647
DE - Germania 1.251
HK - Hong Kong 940
SE - Svezia 921
BR - Brasile 681
VN - Vietnam 505
GB - Regno Unito 382
BG - Bulgaria 321
FR - Francia 240
CA - Canada 229
RU - Federazione Russa 210
IN - India 201
CI - Costa d'Avorio 193
FI - Finlandia 193
TR - Turchia 179
AT - Austria 164
JP - Giappone 120
UA - Ucraina 115
KR - Corea 103
NL - Olanda 94
BD - Bangladesh 67
SN - Senegal 66
IQ - Iraq 50
CH - Svizzera 49
AR - Argentina 43
PL - Polonia 41
MX - Messico 40
PK - Pakistan 36
EE - Estonia 33
BE - Belgio 32
ZA - Sudafrica 32
SA - Arabia Saudita 29
EC - Ecuador 27
ES - Italia 27
ID - Indonesia 25
CO - Colombia 23
MA - Marocco 22
UZ - Uzbekistan 20
VE - Venezuela 18
GR - Grecia 15
CR - Costa Rica 14
CZ - Repubblica Ceca 14
IE - Irlanda 12
TW - Taiwan 12
CL - Cile 11
IL - Israele 11
IR - Iran 11
JM - Giamaica 11
JO - Giordania 11
PH - Filippine 11
AZ - Azerbaigian 10
DZ - Algeria 10
KE - Kenya 10
AE - Emirati Arabi Uniti 9
LT - Lituania 9
PS - Palestinian Territory 9
GT - Guatemala 8
HN - Honduras 8
HU - Ungheria 8
PE - Perù 8
PY - Paraguay 8
RO - Romania 8
UY - Uruguay 8
AU - Australia 7
PA - Panama 7
PT - Portogallo 7
TN - Tunisia 7
EG - Egitto 6
OM - Oman 6
BY - Bielorussia 5
MY - Malesia 5
BO - Bolivia 4
DO - Repubblica Dominicana 4
ET - Etiopia 4
LB - Libano 4
NI - Nicaragua 4
RS - Serbia 4
SK - Slovacchia (Repubblica Slovacca) 4
TT - Trinidad e Tobago 4
AL - Albania 3
BH - Bahrain 3
BS - Bahamas 3
EU - Europa 3
KG - Kirghizistan 3
KZ - Kazakistan 3
SY - Repubblica araba siriana 3
TH - Thailandia 3
XK - ???statistics.table.value.countryCode.XK??? 3
BJ - Benin 2
DK - Danimarca 2
GE - Georgia 2
LK - Sri Lanka 2
MM - Myanmar 2
MT - Malta 2
PR - Porto Rico 2
AI - Anguilla 1
AO - Angola 1
Totale 26.187
Salva come PNG Salva come JPEG
Città #
Ashburn 1.381
Singapore 996
Hong Kong 917
Dallas 899
Fairfield 839
Woodbridge 800
San Jose 709
Ann Arbor 696
Chandler 640
Santa Clara 633
Houston 578
Milan 369
Seattle 354
Shanghai 342
Cambridge 323
Beijing 319
Sofia 317
Wilmington 280
New York 261
Council Bluffs 199
Los Angeles 198
Abidjan 193
Boardman 171
Serra 154
Vienna 150
Princeton 149
Ho Chi Minh City 146
Ottawa 137
Munich 134
Lauterbourg 122
Hefei 121
Jacksonville 121
Rome 121
Lawrence 120
Pisa 111
Frankfurt am Main 103
Medford 103
Tokyo 101
Florence 100
Seoul 98
Hanoi 88
London 84
Des Moines 83
Izmir 75
Buffalo 71
Nanjing 71
Helsinki 70
Dearborn 67
Dakar 66
Istanbul 61
Dong Ket 56
Boulder 54
Redondo Beach 54
Bremen 53
Naples 52
São Paulo 50
Redwood City 42
San Diego 42
Bologna 40
Orem 40
Washington 39
Lancaster 38
Bern 37
Fuzhou 37
Columbus 33
Turku 32
Tianjin 31
Atlanta 29
Genoa 29
Baghdad 27
Brussels 27
Düsseldorf 27
Phoenix 27
Belo Horizonte 26
Chicago 26
Montreal 26
Ogden 24
Grafing 23
Mumbai 23
Rio de Janeiro 23
Shenyang 23
Toronto 23
Changsha 22
Redmond 22
Nanchang 21
Jüchen 20
Lucca 20
San Francisco 20
Warsaw 19
Cascina 18
Brooklyn 17
Kunming 17
Palermo 17
Tashkent 17
Amsterdam 16
Hangzhou 16
Hebei 16
Johannesburg 16
Pune 16
Quanzhou 16
Totale 16.680
Salva come PNG Salva come JPEG
Nome #
I CARCINOMI PAPILLARI E MIDOLLARI DELLA TIROIDE PRESENTI CONTEMPORANEAMENTE HANNO ORIGINE GENETICA INDIPENDENTE 1.179
L’ANALISI GENETICA DI CARCINOMI PAPILLARI E MIDOLLARI DELLA TIROIDE PRESENTI CONTEMPORANEAMENTE RIVELA LA LORO NATURA CASUALE 351
Polymorphisms within base and nucleotide excision repair pathways and risk of differentiated thyroid carcinoma 322
ALL-TRANS RETINOIC ACID TREATMENT INHIBITS THE GROWTH OF RARb mRNA EXPRESSING THYROID CANCER CELL LINES BUT DOES NOT RE-INDUCE THE EXPRESSION OF THYROID SPECIFIC GENES 262
Anaplastic thyroid carcinoma: from clinicopathology to genetics and advanced therapies 258
Risk of Differentiated Thyroid Carcinoma and Polymorphisms within the Susceptibility Cancer Region 8q24 258
Ciglitazone induces cell growth inhibition in a medullary thyroid carcinoma cell line (TT) likely by an increase of PPARgamma expression 256
A comprehensive meta-analysis of case-control association studies to evaluate polymorphisms associated with the risk of differentiated thyroid carcinoma 251
Medullary thyroid cancer treated with vandetanib: predictors of longer and durable response 249
Association between CYP2E1 polymorphisms and risk of differentiated thyroid carcinoma 248
In silico and in vitro analysis of rare germline allelic variants of RET oncogene associated with medullary thyroid cancer 240
A new germline RET mutation apparently devoid of transforming activity serendipitously discovered in a patient with atrophic autoimmune thyroiditis and primary ovarian failure 234
Ret Genetic Screening in Patients with Medullary Thyroid Cancer and Their Relatives: Experience with 807 Individuals at One Center 233
Identification of a novel point mutation in the RET gene (Ala883Thr), which is associated with medullary thyroid carcinoma phenotype only in homozygous condition 231
A complex MEN2 syndrome, a mixture of 2B and 2A, associated with a new RET germiline deletion. 231
Chromosome 10 and RET gene copy number alterations in hereditary and sporadic Medullary Thyroid Carcinoma 230
Strategies for single base gene editing in an immortalized human cell line by CRISPR/Cas9 technology 229
Targeted Therapy in Thyroid Cancer: State of the Art 228
CLINICAL IMPACT OF RET GENETIC SCREENING IN THE MANAGEMENT OF MEDULLARY THYROID CARCINOMA (MTC) PATIENTS: 20 YEARS OF EXPERIENCE 227
Medullary thyroid carcinoma (MTC) and RET proto-oncogene: Mutation spectrum in the familial cases and a meta-analysis of studies on the sporadic form. 225
Prophylactic central compartment lymph node dissection in papillary thyroid carcinoma: Clinical implications derived from the first prospective randomized controlled single institution study 225
V804M RET MUTATION AND VANDETANIB RESPONSE IN METASTATIC MEDULLARY THYROID CANCER 225
Classical point mutations of RET, BRAF and RAS oncogenes are not shared in papillary and medullary thyroid cancer occurring simultaneously in the same gland 220
Inherited variants in genes somatically mutated in thyroid cancer 220
RET genetic screening of sporadic medullary thyroid cancer (MTC) allows the preclinical diagnosis of unsuspected gene carriers and the identification of a relevant percentage of hidden familial MTC (FMTC) 219
Twenty-Five Years Experience on RET Genetic Screening on Hereditary MTC: An Update on The Prevalence of Germline RET Mutations 216
Polymorphisms within the RET proto-oncogene and risk of sporadic medullary thyroid carcinoma 214
Routine measurement of serum calcitonin in nodular thyroid diseases allows the preoperative diagnosis of unsuspected sporadic medullary thyroid carcinoma. 212
BRAF(V600E) mutation and outcome of patients with papillary thyroid carcinoma: A 15-year median follow-up study 212
RET/PTC rearrangements in Belarus, Ukrainian and Russian pos Chernobyl thyroid tumors 211
Multiple Endocrine Neoplasia type 2 syndromes (MEN 2): results from the ItaMEN network analysis on the prevalence of different genotypes and phenotypes 210
RET point mutations in Thyroid Carcinoma 210
Next generation sequencing revealed RET or RAS mutation in medullary thyroid cancer that were negative at sanger sequencing 210
Serum bone Gla-protein (osteocalcin) in patients with bone metastases from thyroid cancer 208
, Descrizione della prima mutazione omozigote germinale di RET (Ala883->Thr) che non determina l'insorgenza del carcinoma midollare della tiroide in condizioni di eterozigosi 204
TPO genetic variants and risk of differentiated thyroid carcinoma in two European populations. 204
GENETIC SCREENING OF RET CAN IDENTIFY NEW MUTATIONS EVEN AFTER 20 YEARS 200
BRAF(V599E) mutation is the leading genetic event in adult sporadic papillary thyroid carcinomas 199
Genome-wide association study on differentiated thyroid cancer. 199
Pro64His (rs4644) polymorphism within galectin-3 is a risk factor of differentiated thyroid carcinoma and affects the transcriptome of thyrocytes engineered via CRISPR/Cas9 system 197
Novel genome-wide association study-based candidate loci for differentiated thyroid cancer risk. 195
AFTER 20 YEARS, RET GENETIC SCREENING STILL INDENTIFIES NEW GERMILINE AND SOMATIC MUTATIONS 194
Pre- And Post-Operative Circulating Tumoral Dna In Patients With Medullary Thyroid Carcinoma 193
Outcome of classical (CVPTC) and follicular (FVPTC) variants of papillary thyroid cancer: 15 years of follow-up 192
Evidences that the polymorphism Pro-282-Ala within the tumor suppressor gene WWOX is a new risk factor for differentiated thyroid carcinoma 191
Novel genetic variants in differentiated thyroid cancer and assessment of the cumulative risk 189
Post-surgical follow-up of differentiated thyroid cancer. 187
Genetic signature of differentiated thyroid carcinoma susceptibility: a machine learning approach 186
Ruolo putativo di H4 come gene oncosoppressore nella patogenesi del carcinoma papillare della tiroide 186
Clinical, pathological and genetic features of anaplastic and poorly differentiated thyroid cancer: A single institute experience 186
Twenty years of lesson learning: How does the RET genetic screening test impact the clinical management of medullary thyroid cancer? 185
The polymorphism rs2480258 within CYP2E1 is associated with different rates of acrylamide metabolism in vivo in humans 183
Mutazione V804M di RET nel carcinoma midollare della tiroide e risposta al trattamento con vandetanib 182
Vandetanib and the predictive factors of durable response in locally advanced or metastatic medullary thyroid cancer: a single center experience. 182
Correlazione genotipo-fenotipo nelle MEN 2: stato dell’arte dopo 15 anni di conoscenze 181
Impact of routine measurement of serum calcitonin on the diagnosis and outcome of medullary thyroid cancer: experience in 10,864 patients with nodular thyroid disorders 181
Correction: Inherited variants in genes somatically mutated in thyroid cancer 181
Fifty years after the first description, the MEN 2B syndrome diagnosisis still late: description of two recent cases 181
A New MEN2 Syndrome with Clinical Features of Both MEN2A and MEN2B Associated with a New RET Germline Deletion 181
CDKN1B V109G polymorphism a new prognostic factor in sporadic medullary thyroid carcinoma 180
Clinical utility of genetic diagnosis for sporadic and hereditary medullary thyroid carcinoma 177
RET genetic screening of sporadic medullary thyroid cancer (MTC) allows the preclinical diagnosis of unsuspected gene carriers and the identification of a relevant percentage of hidden familial MTC (FMTC) 175
Prevalenza di mutazioni di BRAF e riarrangiamenti RET/PTC e TRK in una serie di carcinomi papillari della tiroide 173
RET/PTC Translocations and Clinico-Pathological Features in Human Papillary Thyroid Carcinoma. 172
RET exon 11 (G691S) polymorphism is significantly more frequent in sporadic medullary thyroid carcinoma than in the general population 172
GENETIC LANDSCAPE OF SOMATIC MUTATIONS IN A LARGE COHORT OF SPORADIC MEDULLARY THYROID CARCINOMAS STUDIED BY NEXT GENERATION TARGETED SEQUENCING 171
MON-524 Prospective Evaluation of Patients with Encapsulated Classical Variant of Papillary Thyroid Cancer and Noninvasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features (NIFTP): Have They A Similar Prognosis? 171
Ca19.9 positivity and doubling time are prognostic factors of mortality in patients with advanced medullary thyroid cancer with no evidence of structural disease progression according to RECIST 170
Modifications in the Papillary Thyroid Cancer Gene Profile Over the Last 15 Years. 169
Obesity and the Risk of Papillary Thyroid Cancer: A Pooled Analysis of Three Case-Control Studies. 168
Differential expression of RET isoforms in normal thyroid tissues, papillary and medullary thyroid carcinomas 168
Il ciglitazone induce inibizione della crescita in cellule di carcinoma midollare della tiroide (TT) verosimilmente dovuta ad un aumentata espressione di PPAR gamma 167
RET/PTC rearrangements in thyroid nodules: Studies in irradiated and not irradiated, malignant and benign thyroid lesions in children and adults 167
MON-490 Calcitonin-Based Thyroidectomy Is a Safe Approach in Patients with Germline RET Mutation and Permits to Delay Surgery in Children 167
Chromosomal alterations in sporadic medullary thyroid carcinoma and correlation with outcome 166
RET /PTC translocations and clinico-pathological features in human papillary thyroid carcinoma 166
Analysis of circulating tumor DNA does not improve the clinical management of patients with locally advanced and metastatic papillary thyroid carcinoma 165
New insights in the molecular signature of advanced medullary thyroid cancer: Evidence of a bad outcome of cases with double RET mutations 164
Impact of Advanced Age on the Clinical Presentation and Outcome of Sporadic Medullary Thyroid Carcinoma 163
Active surveillance in ret gene carriers belonging to families with multiple endocrine neoplasia 163
Somatic mutations of the ret protooncogene in sporadic medullary thyroid carcinoma are not restricted to exon 16 and are associated with tumor recurrence. 161
Clinical evolution of sporadic medullary thyroid carcinoma with biochemical incomplete response after initial treatment 160
Calcitonin estimation in patients with nodular goiter and its significance for early detection of MTC: European comments to the guidelines of the American Thyroid Association 160
Genetic and clinical features of multiple endocrine neoplasia types 1 and 2 159
RET mutation heterogeneity in primary advanced medullary thyroid cancers and their metastases 158
Predictive factors of short and long-term vandetanib response in locally advanced or metastatic medullary thyroid cancer: a single center experience 158
null 157
Circulating miR-26b-5p and miR-451a as diagnostic biomarkers in medullary thyroid carcinoma patients 155
L’ mRNA dei recettori per HGF e EGF (c-Met e EGFR) e’ iperespresso nei tumori papillari della tiroide 155
Papillary Thyroid Carcinoma With Rare exon 15 BRAF Mutation Has Indolent Behavior: A Single-Institution Experience 155
Fenotipo misto MEN2A/MEN2B da nuova mutazione germinale di RET: prima descrizione clinico-genetica e iconografia 155
After 20 Years, RET genetic screening still identifies new germline and somatic mutations 153
Runs of homozygosity and inbreeding in thyroid cancer 153
Clinical Impact Of Ret Genetic Screening Of In The Management Of Medullary Thyroid Carcinoma (MTC) Patients: 20 Years Of Experience 153
The Mutation Profile Of Medullary Thyroid Carcinoma Can Be Different In Primary And Metastatic Tissues 148
Clinical impact of molecular techniques for the presurgical diagnosis of differentiated thyroid cancer diagnosis 148
Whole Tumor Capsule Is Prognostic of Very Good Outcome in the Classical Variant of Papillary Thyroid Cancer 148
Evidence of a Low Prevalence of RAS Mutations in a Large Medullary Thyroid Cancer Series 147
null 146
NIS mRNA and protein expression in thyroid and non thyroid carcinoma 145
Totale 20.321
Salva come PNG Salva come JPEG
Categoria #
all - tutte 73.644
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 73.644
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.460 0 0 33 104 330 186 57 82 75 64 120 409
2022/20232.618 292 394 194 199 231 281 55 208 506 43 168 47
2023/20241.871 191 170 224 128 221 265 138 106 70 55 118 185
2024/20255.166 72 214 94 335 557 516 400 292 500 633 590 963
2025/20266.474 527 930 685 525 646 501 979 301 382 565 234 199
2026/20271.033 139 459 435 0 0 0 0 0 0 0 0 0
Totale 26.589